No detectable resistance to tenofovir disoproxil fumarate in HBeAg+ and HBeAg− patients with chronic hepatitis B after 8 years of treatment von Liu, Y., Corsa, A. C., Buti, M., Cathcart, A. L., Flaherty, J. F., Miller, M. D., Kitrinos, K. M., Marcellin, P., Gane, E. J.

Volltext

Genome-free hepatitis B virion levels in patient sera as a potential marker to monitor response to antiviral therapy von Luckenbaugh, L., Kitrinos, K. M., Delaney IV, W. E., Hu, J.

Volltext

Nonstructural protein 5A resistance profile in patients with chronic hepatitis C treated with ledipasvir‐containing regimens without sofosbuvir von Kitrinos, K. M., Corsa, A. C., Worth, A., Hedskog, C., Brainard, D. M., Miller, M. D., Mo, H.

Volltext

Hepatitis B virus wild-type and rtN236T populations show similar early HBV DNA decline in adefovir refractory patients on a tenofovir-based regimen von Svarovskaia, E. S., Curtis, M., Zhu, Y., Borroto-Esoda, K., Miller, M. D., Berg, T., Lavocat, F., Zoulim, F., Kitrinos, K. M.

Volltext

HBeAg levels at week 24 predict response to 8 years of tenofovir in HBeAg‐positive chronic hepatitis B patients von Wong, D., Littlejohn, M., Yuen, L., Jackson, K., Mason, H., Bayliss, J., Rosenberg, G., Gaggar, A., Kitrinos, K., Subramanian, M., Marcellin, P., Buti, M., Janssen, H. L. A., Gane, E., Locarnini, S., Thompson, A., Revill, P. A.

Volltext

Whole-genome deep sequencing of hepatitis B virus in chronic hepatitis B patients reveals single nucleotide variants associated with baseline HBV DNA levels and HBeAg status von Podlaha, O, Revill, P, Bhardwaj, N, Zhuo, L, Kitrinos, K, Gaggar, A, Jiang, Z, Marcellin, P, Locarnini, S, Chan, H.L

Volltext

On-treatment ALT flares are associated with HBsAg loss in genotype A chronic hepatitis B-infected patients treated with nucleotide analogue therapy von Wong, D, Walsh, R, Hammond, R, Yuen, L, Revill, P, Gaggar, A, Subramanian, M, Kitrinos, K, Locarnini, S, Thompson, A

Volltext

Whole-genome sequencing of patients achieving hepatitis B virus serum antigen loss following tenofovir disoproxil fumerate (TDF) and/or pegylated-interferon α-2a (PEG) therapy von Kleinstein, S.E, Marcellin, P, Chan, H.L, Shea, P.R, Gaggar, A, Kitrinos, K, Jump, B, Subramanian, G.M, Peterson, J, Goldstein, D.B

Volltext

Genomic Analyses of Host-Pathogen Interactions in Chronic Hepatitis B Virus Infection von Chaturvedi, N, Bartha, I, Kitrinos, K, Gaggar, A, Ge, D, Subramanian, M, Goldstein, D, Revill, P, Thompson, A, Fellay, J

Volltext

On-treatment decline in HBeAg level at week 24 predicts for HBeAg seroconversion during long-term tenofovir therapy for HBeAg-positive CHB von Wong, D, Littlejohn, M, Yuen, L, Jackson, K, Mason, H, Gaggar, A, Kitrinos, K, Subramanian, M, Marcellin, P, Buti, M, Janssen, H, Gane, E, Bayliss, J, Sozzi, V, Colledge, D, Locarnini, S, Thompson, A, Revill, P

Volltext

P0633 : Association of hepatitis B virus genetic diversity with tenofovir disoproxil fumarate response rates in immune tolerant chronic hepatitis B patients von Lara, J, Thai, H, Kitrinos, K, Xia, G, Gaggar, A, Paulson, M, Ganova-Raeva, L, Khudyakov, Y

Volltext

The Presence of BCP/PC Variants Reduces the Rate of HBsAg Loss among HBeAg-Positive CHB Patients Treated with Long-Term Tenofovir DF Therapy von Thompson, A, Bayliss, J, Yuen, L, Littlejohn, M, Jackson, K, Wong, D, Gaggar, A, Kitrinos, K, Subramanian, M, Marcellin, P, Gane, E, Chan, H, Bowden, S, Locarnini, S, Revill, P

Volltext

O015 : Quantitative measurements of mutations in basal core promotor region suggest a loss of immune tolerance in HBeAg positive chronic hepatitis B infections von Rosenberg, G, Bayliss, J, Yuen, L, Gaggar, A, Kitrinos, K, Subramanian, M, Gane, E, Chan, H.L, Hammond, R, Bowden, S, Revill, P, Locarnini, S, Thompson, A

Volltext

A Phase 3 Study of Tenofovir Alafenamide Compared with Tenofovir Disoproxil Fumarate in Patients with Hbeag-Positive Chronic Hbv: Week 48 Efficacy and Safety Results von Chan, H.L.Y, Fung, S, Seto, W.K, Chuang, W.-L, Chen, C.-Y, Kim, H.J, Hui, A.J, Janssen, H.L.A, Chowdhury, A, Tsang, T.Y.O, Mehta, R, Gane, E, Flaherty, J.F, Massetto, B, Kitrinos, K, Dinh, P, Subramanian, G.M, McHutchison, J.G, Lim, Y.-S, Acharya, S.K, Agarwal, K

Volltext

P0665 : HBV variants present in treatment naïve patients can predict response to NA therapy in immune clearance disease von Bayliss, J, Rosenberg, G, Thompson, A, Gaggar, A, Kitrinos, K, Subramanian, M, Marcellin, P, Gane, E, Chan, H.L, Li, X, Colledge, D, Yuen, L, Littlejohn, M, Edwards, R, Jackson, K, Bonanzinga, S, Hammond, R, Bowden, S, Locarnini, S, Revill, P

Volltext

P0605 : Genotype specific variation in the basal core promoter and pre core regions impacts HBeAg levels during immune clearance disease von Bayliss, J, Rosenberg, G, Thompson, A, Gaggar, A, Kitrinos, K, Subramanian, M, Marcellin, P, Gane, E, Chan, H.L, Li, X, Colledge, D, Yuen, L, Littlejohn, M, Edwards, R, Jackson, K, Bonanzinga, S, Hammond, R, Bowden, S, Locarnini, S, Revill, P

Volltext

P653 RECLASSIFICATION OF IMMUNOTOLERANT CHRONIC HEPATITIS B INFECTION; DETECTION OF HBV VARIANTS WITH IMPLICATIONS FOR HBV DNA, HBsAg AND HBeAg LEVELS von Rosenberg, G, Bayliss, J, Gaggar, A, Kitrinos, K, Subramanian, M, Gane, E, Chan, H.L, Hammond, R, Bowden, S, Revill, P, Locarnini, S, Thompson, A

Volltext

P1048 NUCLEOS(T)IDE ANALOGUE (NA) THERAPY FOR PERSONS IN THE IMMUNOTOLERANT PHASE OF CHB IS ASSOCIATED WITH SIGNIFICANT DECLINE IN HBeAg AND HBsAg LEVELS von Rosenberg, G, Bayliss, J, Gaggar, A, Kitrinos, K, Subramanian, M, Gane, E, Chan, H.L, Hammond, R, Bowden, S, Revill, P, Locarnini, S, Thompson, A

Volltext

P672 HBeAg LEVELS DIFFER ACCORDING TO HBV GENOTYPE IN IMMUNE CLEARANCE DISEASE von Bayliss, J, Thompson, A, Rosenberg, G, Gaggar, A, Kitrinos, K, Gane, E, Chan, H.L, Li, X, Littlejohn, M, Yuen, L, Edwards, R, Jackson, K, Bonanzinga, S, Hammond, R, Bowden, S, Locarnini, S, Revill, P

Volltext

101 TENOFOVIR DF (TDF) COMPARED TO EMTRICITABINE (FTC)/TDF IN HBeAg-POSITIVE, CHRONIC HEPATITIS B (CHB) VIRUSINFECTED PATIENTS IN THE IMMUNE TOLERANT (IT) PHASE von Chan, H.L, Chan, C.K, Hui, A.J, Chan, S, Poordad, F, Chang, T.-T, Mathurin, P, Flaherty, J.F, Lin, L, Kitrinos, K, Subramanian, G.M, McHutchison, J.G, Lee, S, Gane, E

Volltext